Compound ID | 3328
A42867
Class: Glycopeptide
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against aerobic and anaerobic Gram-positives |
| Description: | Natural product from Nocardia sp.; ristocetin-vancomycin type; shows an effective dose (ED50) of 1.54 gm/kg in Streptococcus pyogenes infected mice; inferior to teicoplanin in treating mice infected with Enterococcus faecalis or Clostridium difficile; similar to vancomycin and teicoplanin in treating mice infected with coagulase-negative Staphylococcus aureus |
| Institute where first reported: | Merrell Dow Research Institute, Lepetit Reseach Center |
| Year first mentioned: | 1989 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://www.jstage.jst.go.jp/article/antibiotics1968/42/4/42_4_497/_article/-char/en |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.